■ 試験デザイン

STUDY SELECTION:Placebo controlled randomised trials comprising at least 50 participants with type 2 diabetes treated with DPP-4 inhibitors and sulphonylureas.

T システマティックレビュー
P SU薬を使用中の糖尿病患者
E DPP4阻害薬
C プラセボ
O 低血糖の出現

■ 結果

The risk ratio of hypoglycaemia was 1.52 (95% confidence interval 1.29 to 1.80). The NNH was 17 (95% confidence interval 11 to 30) for a treatment duration of six months or less, 15 (9 to 26) for 6.1 to 12 months, and 8 (5 to 15) for more than one year. In subgroup analysis, no difference was found between full and low doses of DPP-4 inhibitors: the risk ratio related to full dose DPP-4 inhibitors was 1.66 (1.34 to 2.06), whereas the increased risk ratio related to low dose DPP-4 inhibitors did not reach statistical significance (1.33, 0.92 to 1.94).



■ 参照文献
Salvo F et al., BMJ. 2016 May 3;353:i2231. PMID: 27142267